Arthritis, Musculoskeletal And Skin Diseases Research in FY2024

How Arthritis, Musculoskeletal And Skin Diseases Research meets FY2024 on USAspending

$3,658,597,930.82 is the obligation sum on the intersection of CFDA 93.846 and fiscal year 2024. The FY cell is 84.8% of the program-wide $4,315,511,081.33 book in this extract. It is not every federal dollar tagged to FY2024, not the listing’s all-year $4,315,511,081.33 book restated as one year, and not an outlay. FEC donations do not fund these USAspending obligations. This packet lists no award recipients.

CFDA 93.846 (/programs/93.846/) drops the year filter. FY2024 federal spending (/fiscal-years/2024/) drops the CFDA filter. All programs (/programs/) and All spending ties (/ties/) are parent indexes. Only this page applies both filters at once. A later ingest can restate $3,658,597,930.82 without changing the join keys.

What CFDA 93.846 contributes to the pair

Official catalog string: ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH. Display name: Arthritis, Musculoskeletal And Skin Diseases Research. Program-wide obligations in this extract are $4,315,511,081.33 across 2,683 awards. Those parent figures are not the FY2024 headline. Mixing the listing with other arthritis or musculoskeletal catalog lines that are not CFDA 93.846 would invent a combined book. Arthritis, Musculoskeletal And Skin Diseases Research is the display name on CFDA 93.846. FY2024 is one yearlyTrend bucket on that listing, not a claim that every obligated dollar was spent inside calendar 2024 on a named disease site. The packet publishes no investigator names and no clinic roster. Keep the catalog title and FY2024 on the same citation.

What fiscal year 2024 contributes to the pair

FY2024 is a USAspending fiscal-year key, not a calendar year and not a finished cash year. FY figures can be incomplete. Awards that carry a different year sit outside this cell even if the listing is still Arthritis, Musculoskeletal And Skin Diseases Research. Do not annualize $3,658,597,930.82 into a run-rate the packet never computed.

2,043 FY2024 award records are not 2,043 finished trials or 2,043 unique laboratories

2,043 is the year-cell award-record count, not 2,043 finished trials or 2,043 unique laboratories. About $1,790,796.83 per year-cell record is arithmetic on $3,658,597,930.82 and 2,043, not a typical payment. The parent’s 2,683 awards belong on CFDA 93.846 without the year filter. Unique recipients remain unpublished.

Caveats on Arthritis, Musculoskeletal And Skin Diseases Research obligations in FY2024

An obligation is a commitment. An outlay is a Treasury payment. $3,658,597,930.82 is the commitment figure. The join cannot support a named-lab roster, a principal-investigator directory, or a tissue-type split. Keep the obligation label. If a chart mixes other arthritis or musculoskeletal catalog lines that are not CFDA 93.846 with CFDA 93.846 in FY2024, the chart has left this join.

Hubs: /programs/93.846/ (CFDA 93.846), /fiscal-years/2024/ (FY2024 federal spending), /programs/ (All programs), /ties/ (All spending ties). None convert this cell into a recipient list. Cite Arthritis, Musculoskeletal And Skin Diseases Research, FY2024, CFDA 93.846, $3,658,597,930.82, 2,043 awards, USAspending.gov, obligations only. Keep Arthritis, Musculoskeletal And Skin Diseases Research and FY2024 on the same line as $3,658,597,930.82. CFDA 93.846 remains the program key; fiscal year 2024 remains the time key. Obligations of $3,658,597,930.82 are not outlays and not a named-lab roster, a principal-investigator directory, or a tissue-type split. Original filings remain on USAspending.gov for this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. Unique recipients remain unpublished on this program-year join. All programs and All spending ties are larger indexes than this cell. A later USAspending ingest can restate $3,658,597,930.82 without changing CFDA 93.846 or FY2024. Do not invent contractors or award recipients for Arthritis, Musculoskeletal And Skin Diseases Research. The 2,043 year-cell awards are still not 2,043 finished trials or 2,043 unique laboratories. Keep Arthritis, Musculoskeletal And Skin Diseases Research and FY2024 on the same line as $3,658,597,930.82.

Questions

How much Arthritis, Musculoskeletal And Skin Diseases Research spending is in FY2024?

USAspending.gov records $3,658,597,930.82 in Arthritis, Musculoskeletal And Skin Diseases Research obligations for FY2024 (CFDA 93.846). That is a program × year join, not an outlay and not the government-wide FY2024 total. Original filings remain on USAspending.gov.

Do 2,043 awards mean 2,043 arthritis studies finished in FY2024?

No. 2,043 is the year-cell award-record count, not 2,043 finished trials or 2,043 unique laboratories. A mean of about $1,790,796.83 is arithmetic on packet facts, not a typical payment. Unique recipients are unpublished. Original filings remain on USAspending.gov.

Is $3,658,597,930.82 cash already paid for Arthritis, Musculoskeletal And Skin Diseases Research in FY2024?

No. $3,658,597,930.82 is an obligation aggregate for Arthritis, Musculoskeletal And Skin Diseases Research in FY2024. Outlays, remaining balances, and cash already paid are unpublished on this packet. Keep the obligation label. USAspending.gov remains the source.

Which pages parent Arthritis, Musculoskeletal And Skin Diseases Research FY2024?

CFDA 93.846 is the program parent. FY2024 federal spending is the year parent. All programs lists other CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Arthritis, Musculoskeletal And Skin Diseases Research × FY2024 at $3,658,597,930.82.